Viking Therapeutics (VKTX)
(Real Time Quote from BATS)
$79.44 USD
+4.02 (5.33%)
Updated Apr 30, 2024 02:48 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VKTX 79.44 +4.02(5.33%)
Will VKTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
Brian Big Idea On Technical Analysis
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
Other News for VKTX
10 Health Care Stocks With Whale Alerts In Today's Session
Check Out What Whales Are Doing With VKTX
3 Best Stocks to Buy Now, 4/30/2024, According to Top Analysts
Viking Therapeutics (VKTX) Gets a Buy from Truist Financial
Roche: Value Remains Despite Covid-19 Revenue Growth Loss